AU752072B2 - N-benzyl-3-indenylacetamides derivatives for treating neoplasia - Google Patents

N-benzyl-3-indenylacetamides derivatives for treating neoplasia Download PDF

Info

Publication number
AU752072B2
AU752072B2 AU14981/99A AU1498199A AU752072B2 AU 752072 B2 AU752072 B2 AU 752072B2 AU 14981/99 A AU14981/99 A AU 14981/99A AU 1498199 A AU1498199 A AU 1498199A AU 752072 B2 AU752072 B2 AU 752072B2
Authority
AU
Australia
Prior art keywords
methyl
fluoro
benzyl
indenylacetamide
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU14981/99A
Other languages
English (en)
Other versions
AU1498199A (en
Inventor
Klaus Brendel
Paul Gross
Rifat Pamukcu
Gary Piazza
Gerhard Sperl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
University of Arizona
Original Assignee
Cell Pathways Inc
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/989,353 external-priority patent/US5948779A/en
Application filed by Cell Pathways Inc, University of Arizona filed Critical Cell Pathways Inc
Publication of AU1498199A publication Critical patent/AU1498199A/en
Application granted granted Critical
Publication of AU752072B2 publication Critical patent/AU752072B2/en
Assigned to UNIVERSITY OF ARIZONA, THE, OSI PHARMACEUTICALS, INC. reassignment UNIVERSITY OF ARIZONA, THE Alteration of Name(s) in Register under S187 Assignors: CELL PATHWAYS, INC., UNIVERSITY OF ARIZONA, THE
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU14981/99A 1997-12-12 1998-12-11 N-benzyl-3-indenylacetamides derivatives for treating neoplasia Ceased AU752072B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/989,353 US5948779A (en) 1997-12-12 1997-12-12 Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes
US08/989353 1997-12-12
US09/206,245 US6066634A (en) 1997-12-12 1998-12-07 Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia
US09/206245 1998-12-07
PCT/GB1998/003712 WO1999031065A1 (en) 1997-12-12 1998-12-11 N-benzyl-3-indenylacetamides derivatives for treating neoplasia

Publications (2)

Publication Number Publication Date
AU1498199A AU1498199A (en) 1999-07-05
AU752072B2 true AU752072B2 (en) 2002-09-05

Family

ID=26901185

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14981/99A Ceased AU752072B2 (en) 1997-12-12 1998-12-11 N-benzyl-3-indenylacetamides derivatives for treating neoplasia

Country Status (18)

Country Link
US (3) US6166053A (enExample)
EP (1) EP1044187B1 (enExample)
JP (1) JP4307719B2 (enExample)
CN (1) CN100436418C (enExample)
AT (1) ATE257152T1 (enExample)
AU (1) AU752072B2 (enExample)
BR (1) BR9813540A (enExample)
CA (1) CA2314339C (enExample)
CZ (1) CZ298826B6 (enExample)
DE (1) DE69820908T2 (enExample)
ES (1) ES2212383T3 (enExample)
HU (1) HU227153B1 (enExample)
IL (1) IL136603A0 (enExample)
NO (1) NO317097B1 (enExample)
NZ (1) NZ504958A (enExample)
PL (1) PL196936B1 (enExample)
TR (1) TR200001687T2 (enExample)
WO (1) WO1999031065A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2314339C (en) * 1997-12-12 2009-09-08 Cell Pathways, Inc. N-benzyl-3-indenylacetamide derivatives for treating neoplasia
IL132366A0 (en) * 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds
AU2001255849B8 (en) * 2000-04-19 2006-04-27 Lilly Icos, Llc. PDE-V inhibitors for treatment of Parkinson's Disease
DE10058663A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
WO2002067936A1 (en) * 2001-02-21 2002-09-06 Cell Pathways, Inc. Methods for treatment of inflammatory bowel disease
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
US20030073740A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of lupus erythematosus
US6479493B1 (en) * 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
CN100398522C (zh) * 2003-08-20 2008-07-02 Irm责任有限公司 组织蛋白酶s的抑制剂
US6995622B2 (en) * 2004-01-09 2006-02-07 Robert Bosh Gmbh Frequency and/or phase compensated microelectromechanical oscillator
CA2568906C (en) 2004-06-02 2010-09-21 Merit Diamond Corporation Comfort interior for jewelry and jewelry including that interior
CN1332930C (zh) * 2005-08-05 2007-08-22 中国科学院上海有机化学研究所 制备乙氰菊酯前体的方法
CA2635093C (en) * 2006-01-04 2012-06-26 Southern Research Institute Derivatives of sulindac, use thereof and preparation thereof
WO2009022756A1 (ja) * 2007-08-13 2009-02-19 Katayama Chemical Industries Co., Ltd. 虚血性疾患の診断及び治療
EP2365746B1 (en) * 2008-11-04 2014-07-16 Wellstat Therapeutics Corporation Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids
CN109703393A (zh) 2009-08-07 2019-05-03 奥克兰联合服务有限公司 感应电力传递装置
US20160168108A1 (en) 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
US9862698B2 (en) 2014-12-16 2018-01-09 Adt Pharmaceuticals, Inc. Indenyl compounds, pharmaceutical compositions, and medical uses thereof
CN112020354A (zh) 2018-04-26 2020-12-01 Adt制药有限责任公司 抗癌茚类、茚满类、氮杂茚类、氮杂茚满类、药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650720B2 (en) * 1991-03-08 1994-06-30 Fgn, Inc. Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof
US6063818A (en) * 1996-06-13 2000-05-16 Cell Pathways Inc. Substituted benzylidene indenyl formamides, acetamides and propionamides
US5948779A (en) * 1997-12-12 1999-09-07 Cell Pathways, Inc. Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes
CA2314339C (en) * 1997-12-12 2009-09-08 Cell Pathways, Inc. N-benzyl-3-indenylacetamide derivatives for treating neoplasia

Also Published As

Publication number Publication date
NZ504958A (en) 2003-03-28
PL341151A1 (en) 2001-03-26
PL196936B1 (pl) 2008-02-29
NO20002972L (no) 2000-08-09
CA2314339A1 (en) 1999-06-24
US6426349B1 (en) 2002-07-30
EP1044187A1 (en) 2000-10-18
HUP0100170A3 (en) 2001-12-28
TR200001687T2 (tr) 2000-10-23
DE69820908T2 (de) 2004-12-23
ATE257152T1 (de) 2004-01-15
AU1498199A (en) 1999-07-05
NO20002972D0 (no) 2000-06-09
NO317097B1 (no) 2004-08-09
HUP0100170A1 (hu) 2001-07-30
DE69820908D1 (de) 2004-02-05
CZ298826B6 (cs) 2008-02-20
WO1999031065A1 (en) 1999-06-24
CA2314339C (en) 2009-09-08
BR9813540A (pt) 2000-10-10
ES2212383T3 (es) 2004-07-16
EP1044187B1 (en) 2004-01-02
IL136603A0 (en) 2001-06-14
HU227153B1 (en) 2010-08-30
CZ20002157A3 (cs) 2000-10-11
JP2002508358A (ja) 2002-03-19
US20030009033A1 (en) 2003-01-09
US6166053A (en) 2000-12-26
JP4307719B2 (ja) 2009-08-05
US6610854B2 (en) 2003-08-26
CN100436418C (zh) 2008-11-26
CN1281436A (zh) 2001-01-24

Similar Documents

Publication Publication Date Title
AU752072B2 (en) N-benzyl-3-indenylacetamides derivatives for treating neoplasia
US6066634A (en) Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia
US6403831B1 (en) Substituted benzylidene indenyl formamides, acetamides and propionamides
US6028116A (en) Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia
US6538029B1 (en) Methods for treatment of renal cell carcinoma
US6180629B1 (en) [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6486158B1 (en) [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia
US6465494B1 (en) Methods for treatment of cystic fibrosis
HUP9903620A2 (hu) Helyettesített benzilidén-indenil-formamid-, -acetamid- és -propionamid- származékokat tartalmazó gyógyászati készítmények,valamint ezen vegyületek alkalmazása
HK1030947B (en) N-benzyl-3-indenylacetamides derivatives for treating neoplasia
US20030073741A1 (en) Methods for treatment of multiple sclerosis
US20030073740A1 (en) Methods for treatment of lupus erythematosus
US20060100210A1 (en) Methods for treatment of scleroderma
HK1020170B (en) Substituted benzylidene indenyl formamides, acetamides and propionamides

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: OSI PHARMACEUTICALS, INC., THE UNIVERSITY OF ARIZO

Free format text: FORMER OWNER WAS: CELL PATHWAYS, INC., THE UNIVERSITY OF ARIZONA